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The steroidal-based drug 2-ethyloestradiol-3,17-O,O-bis-sulphamate (STX243) has been developed as a potent antiangiogenic and
antitumour compound. The objective of this study was to ascertain whether STX243 is more active in vivo than the clinically relevant
drug 2-methoxyoestradiol (2-MeOE2) and the structurally similar compound 2-MeOE2-3,17-O,O-bis-sulphamate (STX140). The
tumour growth inhibition efficacy, antiangiogenic potential and pharmacokinetics of STX243 were examined using four in vivo models.
Both STX243 and STX140 were capable of retarding the growth of MDA-MB-231 xenograft tumours (72 and 63%, respectively),
whereas no inhibition was observed for animals treated with 2-MeOE2. Further tumour inhibition studies showed that STX243 was
also active against MCF-7 paclitaxel-resistant tumours. Using a Matrigel plug-based model, in vivo angiogenesis was restricted with
STX243 and STX140 (50 and 72%, respectively, using a 10mgkg
 1 oral dose), thereby showing the antiangiogenic activity of both
compounds. The pharmacokinetics of STX243 were examined at two different doses using adult female rats. The compound was
orally bioavailable (31% after a single 10mgkg
 1 dose) and resistant to metabolism. These results show that STX243 is a potent in
vivo drug and could be clinically effective at treating a number of oncological conditions.
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The hypothesis that tumour development is dependent on
angiogenesis was originally proposed by Folkman (1971). This
discovery has lead to the development of numerous antiangiogenic
inhibitors for treating a variety of diseases, including lung and
colon cancer (Eskens, 2004; Folkman, 2006).
An angiogenesis inhibitor that is currently under clinical
investigation is the steroidal-based compound 2-methoxyoestra-
diol (2-MeOE2; Figure 1.1) (Kerbel and Folkman, 2002). The
biological properties of 2-MeOE2 were first investigated by Fotsis
et al (1994). In vitro studies have shown that 2-MeOE2 has
antiproliferative and proapoptotic effects on endothelial cells
(Fotsis et al, 1994; Tsukamoto et al, 1998). However, high
concentrations of drug are required in vivo to inhibit tumour
growth, and some studies have shown that 2-MeOE2 is ineffective
at suppressing the growth of certain tumours (Fotsis et al, 1994;
Ryschich et al, 2003; Ireson et al, 2004). In addition, clinical trials
have shown that 2-MeOE2 needs to be administered at doses
ranging from 200 to 1200mg to achieve a therapeutic effect in
prostate and breast cancer patients (Lakhani et al, 2003; Sweeney
et al, 2005; Dahut et al, 2006). The pharmacological properties of
2-MeOE2 may be responsible for the relatively high dose of drug
required in these studies. A recent study has shown that 2-MeOE2
was rapidly converted to inactive 2-methoxyoestrone in cells that
expressed high levels of 17b-hydroxysteroid dehydrogenase type 2
(Newman et al, 2006), an enzyme that is expressed at high
concentrations in the epithelial cells of the gastrointestinal tract
(Mustonen et al, 1998). This finding may explain why an extensive
metabolism of 2-MeOE2 to 2-methoxyoestrone was observed in a
phase I study of 15 patients with metastatic breast cancer (Lakhani
et al, 2003). 2-Methoxyoestradiol shows very poor oral bioavail-
ability; no detectable concentrations of the drug were found in the
plasma of female Wistar rats after they had received a single
10mgkg
 1 oral dose (Ireson et al, 2004). In support of this finding,
a phase I trial was terminated because of the very low levels of
2-MeOE2 detected in the patients’ plasma (Dahut et al, 2006). New
steroidal-based compounds are currently being developed with the
objective of increasing potency and oral bioavailability. Two of
these compounds currently under preclinical investigation are
2-MeOE2-3,17-O,O-bis-sulphamate (STX140; Figure 1.2) and
2-ethyloestradiol-3,17-O,O-bis-sulphamate (STX243; Figure 1.3).
Earlier investigations have shown that STX140 is a potent
anticancer compound both in vitro and in vivo. STX140 was found
to inhibit human umbilical vein endothelial cell (HUVEC)
proliferation, a model widely used for studying angiogenesis. This
study showed that STX140 was 60-fold more effective than
2-MeOE2 at inhibiting proliferation (Newman et al, 2004). Earlier
studies have also shown that STX140 initiates apoptosis, possibly by
phosphorylating BCL-2 and activating caspases 3 and 9 (Day et al,
2003; Wood et al, 2004). In vitro STX140 has been shown to inhibit
cell proliferation, including preventing the growth of cells that are
resistant to conventional chemotherapeutic agents (Suzuki et al,
2003; Raobaikady et al, 2005). In vivo investigations have shown
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sthat STX140 is orally effective at inhibiting the growth of both
oestrogen-receptor-positive (ERþ) and oestrogen-receptor-
negative (ER ) tumours (Ireson et al, 2004; Utsumi et al, 2005).
In contrast, when 2-MeOE2 is administered at the same dose, no
inhibition of tumour growth was observed (Ireson et al, 2004).
STX140 overcomes the oral bioavailability problems encountered
with 2-MeOE2. When female Wistar rats received a single
10mgkg
 1 oral dose, significant concentrations of STX140 were
found in plasma after 24h. In the same study, 85% oral
bioavailability was attained and no major metabolic products of
STX140 were identified (Ireson et al, 2004).
Preliminary investigations have been performed to examine the
in vitro properties of STX243. Studies conducted with a range of
cell lines have shown that STX243 is equipotent to STX140 at
inhibiting cell proliferation (Suzuki et al, 2003; Raobaikady et al,
2005). Novel experiments recently conducted by our group have
shown that STX243, and also STX140, induce G2/M arrest and
apoptosis in cells recovered from xenograft tumours (Foster et al,
2008).
In this study, investigations were undertaken to compare the in
vivo efficacy of STX243 with STX140 and 2-MeOE2. Tumour
growth inhibition was assessed in two breast cancer animal
models. MDA-MB-231 xenograft tumours were used to compare
the in vivo efficacy of all three compounds, and a tumour
resistance study was conducted to investigate the ability of STX243
to inhibit the growth of paclitaxel-resistant MCF-7dox40 xenograft
tumours. The antiangiogenic potential of STX243 was also
evaluated using an established Matrigel plug-based methodology
(Passaniti et al, 1992; Prewett et al, 1999; Chander et al,
2007). To ascertain whether the biological properties of STX243
could overcome the oral bioavailability problems encountered
with 2-MeOE2, the pharmacokinetics of STX243 were examined
in adult female Wistar rats. The pharmacokinetics of STX140
and 2-MeOE2 have been evaluated earlier by our group
(Ireson et al, 2004).
MATERIALS AND METHODS
Compound synthesis
2-Methoxyoestradiol, STX140, STX243 and its putative metabolite
2-ethyloestradiol-17-O-sulphamate (STX1813) were synthesised as
described earlier (Leese et al, 2005, 2006). Spectroscopic and
analytical data were obtained in accordance with each compound’s
structure. The purity of the compounds was confirmed through the
use of high-performance liquid chromatography (HPLC). CLogP
(Leo, 2003) was calculated using ChemOffice 2008, Cambridgesoft,
Cambridge, MA, USA.
Angiogenesis assay
The effects of the compounds on in vitro vessel formation were
assessed using an angiogenesis kit (TCS Cellworks, Claydon, UK).
For this assay, HUVECs (obtained from TCS Cellworks) were
cultured in a 24-well plate within a matrix of human diploid
fibroblasts of dermal origin in an optimised medium (TCS
Cellworks) supplemented with 2ngml
 1 vascular endothelial
growth factor (VEGF). The cocultured cells were incubated
throughout the experiment at 371C under 5% CO2 in a humidified
incubator. On day 1, the culture medium was removed and
replaced with medium containing the compounds under investiga-
tion. The vehicle used for the dilution of compound was
tetrahydrofuran (THF). The final concentration of THF in the
medium was 0.001 (100nM dose) to 0.00025% (25nM dose). On
days 4, 7 and 9, the medium was replaced with fresh medium
containing the compounds. Each compound was tested in triplicate.
On day 11, the cells were washed (phosphate-buffered saline) and
70% ethanol (1ml) was added to each well for 30min to fix the
cells. After fixation, the cells were washed with blocking buffer
(1ml, phosphate-buffered salineþ1% bovine serum albumin) and
stained for CD31 according to the manufacturer’s instructions
(TCS Cellworks).
The extent of vessel formation was then quantified using a
variation of an earlier described technique (Newman et al, 2004).
Briefly, using a high-resolution transmissive scanner (ScanMaker
9800, Microtek, Willich, Germany), each well was scanned and
saved as a tagged image format (TIF) file in Photoshop (Adobe,
San Jose, CA, USA). The image was then converted to a black and
white image using the photocopy filter in Photoshop ( 2, 10
detail and 25 darkness) and saved as an uncompressed TIF file.
The files were transferred to the AngioSys software (TCS
Cellworks), all background and non-tubule-like structures
were removed using erode ( 1) and clean (100 pixels) functions,
and the number of pixels representing vessels was counted. This
technique was validated (data not shown) against the quantifica-
tion techniques as described earlier (Newman et al, 2004).
In vivo experiments
All animal experiments were conducted in accordance with the
United Kingdom Co-ordinating Committee on Cancer Research
(UKCCCR) guidelines for the Welfare of Animals in Experimental
Neoplasia (Workman et al, 1998) and approved by the Imperial
College Ethical Review Committee. The animals were maintained
in positive pressure isolators with 12h light and dark cycles. Food
and water were available to the animals ad libitum. The rats
received expanded RM1 polylined diet, whereas the mice received
irradiated CRM pellets (Special Diet Services, Witham, Essex, UK).
Tumour growth inhibition models
The tumour growth inhibition efficacy of STX243 was investigated
in two different breast cancer mice models. In both models the
animals were 6 weeks of age at the start of study.
An MDA-MB-231 (ER ) cell-based model was used to compare
the in vivo properties of STX243, STX140 and 2-MeOE2.
The MDA-MB-231 cells were kindly donated by Dr PG Kasprzyk
(IPSEN-Biomeasure, Milford, MA, USA). In this study, 2 10
6 cells
were injected subcutaneously into the flank of female MF-1 nu/nu
mice (Harlan, Bicester, Oxon, UK). Oral administration of vehicle
(10% THF, 90% PG), STX140 (20mgkg
 1),STX243(40mgkg
 1)a n d
R1
R
R2
(3) OSO2NH2 CH2CH3 OSO2NH2
(2) OSO2NH2 OCH3 OSO2NH2
(1) OH OCH3 OH
R2 R1 R
Figure 1 Chemical structures of 2-MeOE2 (1), STX140 (2) and
STX243 (3).
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s2-MeOE2 (40 and 75mgkg
 1) was initiated when the tumours
reached approximately 100mm
3. An earlier study had shown the
efficacy of STX140 at this dose (Ireson et al, 2004). Furthermore,
the maximum-tolerated dose from a single oral administration is
150mgkg
 1 for STX140 and 300mgkg
 1 for STX243 (Foster et al,
2008). The animals were dosed daily for 21 days. Each treatment
group comprised five animals, except for the vehicle-only group
with seven animals. The weight of the animals was recorded at
regular intervals throughout the study. Tumour measurements
were taken every week using electronic calipers and the volume of
the tumours was determined using the formula: length width
2/2
(l w
2/2).
The potential of STX243 to inhibit the growth of paclitaxel-
resistant tumours was investigated using two MCF-7 (ERþ) cell
lines. The MCF-7 wild-type (MCF-7wt) cells were purchased from
the American Type Culture Collection (ATCC; LGC Promochem,
Teddington, Middlesex, UK) and the MCF-7 doxorubicin-resistant
(MCF-7dox40) cells were kindly donated by Dr GL Scheffer
(Department of Pathology, Free University Hospital, Amsterdam,
Netherlands). MCF-7dox40 is a paclitaxel-resistant cell line
because of its overexpression of the multidrug resistance protein,
P-glycoprotein (Scheffer et al, 2000). In this study, 5 10
6
MCF-7wt and MCF-7dox40 cells in Matrigel were injected
subcutaneously into the right and left flank, respectively, of female
MF-1 nu/nu mice. When the tumours reached 70–100mm
3 in
volume, the animals were dosed either orally with STX243 or
vehicle, or intravenously with paclitaxel. The orally dosed animals
received daily administrations of vehicle (10% THF, 90% PG) or
STX243 (40mgkg
 1), whereas the paclitaxel (15mgkg
 1) animals
received weekly intravenous injections of the drug dissolved in
0.9% (w/v) NaCl (saline). The animals were dosed for a total of 28
days with five animals in each treatment group. The weight of the
animals was recorded at regular intervals and the volume of the
tumours was measured on a weekly basis using the formula
described earlier.
In vivo angiogenesis assay
The antiangiogenic potential of STX243 was assessed using a
modified Matrigel plug assay as described earlier (Passaniti et al,
1992; Prewett et al, 1999; Chander et al, 2007). The female C57BL/6J
mice used in this study were obtained from Harlan (Bicester).
The mice were anaesthetised, placed on a heated pad (371C) and
0.5ml of ice-cold Matrigel supplemented with 500ng of basic
fibroblast growth factor (bFGF) was injected subcutaneously into
the flanks of each mouse. Control mice received Matrigel without
bFGF. The mice were subsequently weighed before returning the
mice to their isolator. After 24h of Matrigel injection, the mice
were placed into the following treatment groups: control, bFGF-
only, bFGF plus STX140 (10mgkg
 1, orally) and bFGF plus
STX243 (10, 20 or 40mgkg
 1, orally). Control and bFGF-only
animals were dosed orally with vehicle (10% THF, 90% PG). The
animals were dosed every day for four days with five animals per
treatment group. Quantification of the blood vessels within the
Matrigel plugs was facilitated through the intravenous injection of
100ml of 0.25mgml
 1 FITC-dextran (250000molecular weight)
seven days after the Matrigel injection. FITC-dextran injection
allows for visualisation of the blood vessels that has been recently
formed in the matrigel plugs. The animals were killed 20min after
the injection of the FITC-dextran. The mice were subsequently
weighed and the Matrigel plugs were removed. The Matrigel plugs
were photographed and subsequently dissolved in 1ml Dispase
reagent for 16h at 371C. The resulting mixture was centrifuged at
15700g (201C) for 30s. The fluorescence of the supernatant was
measured using a FLUOstar OPTIMA fluorimeter (BMG Labtech
Ltd., Aylesbury, Bucks, UK). The excitation and emission
wavelengths used were 480 and 520nm, respectively. The
fluorescence of the samples was quantitated using a standard
curve of FITC-dextran (0.4–25mgml
 1).
Pharmacokinetic studies
The pharmacokinetic properties of STX243 were investigated using
female Wistar rats (Charles River, Margate, Kent, UK). The rats
were weighed and STX243 was administered either intravenously
or orally at two different doses (10 or 40mgkg
 1). Control animals
only received vehicle (10% THF, 90% PG). At specified time
intervals after dosing, blood was removed by cardiac puncture
under terminal anaesthesia (isoflurane), the rats were culled
through cervical dislocation and the weight of each rat was
recorded. The time points used in this study were as follows: 5 and
30min; 1, 2, 3, 4, 8 and 24h, with three animals per time point.
Plasma was separated from blood cells by centrifugation (1900g,
41C, 10min) and stored at  801C until it was required for analysis.
After the samples had defrosted, the plasma was divided into
0.5ml samples and progesterone (0.1mM) was added to the sample
to act as an internal standard. Through the use of solid phase
extraction (SPE), STX243 was extracted from the samples under
vacuum using Oasis HLB Extraction Cartridges (Waters, Elstree,
Herts, UK). The column was prepped with methyl-tert-butyl ether,
methanol and water, before passing the sample down the column.
The column was subsequently washed with methanol/water (1:19,
v/v). Elution of the sample was achieved using methanol/methyl-
tert-butyl ether (1:9, v/v). The eluant was evaporated to dryness
under a stream of air at 401C. The residues were analysed
immediately by HPLC. The extraction efficiency of STX243 from
plasma was found to be 54±2% (mean±s.e.m.).
HPLC analysis
Sample analysis was performed using a reverse phase HPLC
method. The residues were reconstituted in mobile phase and
100ml of each sample was injected onto an Agilent 1100
ChemStation HPLC system (Wokingham, Berks, UK). Mobile
phase consisted of 65% methanol in 0.02 M ammonium sulphate
(pH 6.5). STX243, STX1813 and progesterone were separated from
endogenous plasma components using a Gemini 5m C6-Phenyl 110
column (250 3.0mm; Phenomenex, Macclesfield, Cheshire, UK)
and a flow rate of 0.425mlmin
 1. The column temperature was set
at 251C and the samples were analysed using a photodiode array
detector set to 202 or 220nm. Two different wavelengths were used
because preliminary investigations showed that the lower wave-
length was required to analyse the samples that contained low
levels of STX243, and accurate quantification of high concentra-
tions was only achieved when a wavelength of 220nm was
employed. Quantification was achieved by spiking plasma with
known amounts of STX243 and the internal standard, progester-
one, followed by extracting the samples with SPE as outlined
earlier. The concentration of STX243 in the plasma samples was
quantified using linear calibration curves in the range of
6–100000ngml
 1. The limits of detection (LOD) and limits of
quantification were 1.8 and 6ngml
 1, respectively. The intra-day
and inter-day coefficients of variation were 2.9 and 3.8%,
respectively.
Pharmacokinetic analysis
The pharmacokinetic parameters were calculated using WinNonlin
software (Pharsight, Mountain View, CA, USA). A non-compart-
mental model was used to evaluate the plasma concentration data
attained after oral administration. A two-compartmental approach
gave the best approximation to the intravenous data attained. The
pharmacokinetic parameters were attained by initially calculating
the area under the curve (AUC), the area under the first moment vs
time curve (AUMC) and the distribution and elimination constants
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s(a and b). From these results, it was possible to calculate the
following parameters: distribution half-life (t1/2a)¼LN(2)/a,
elimination half-life (t1/2b)¼LN(2)/b, mean residence time
(MRT)¼AUMC/AUC, total body clearance (Cl)¼dose/AUC,
volume of distribution (VD)¼Cl*MRT and bioavailability
(% F)¼(AUCp.o./AUCi.v.) 100.
Statistics
All in vitro experiments were carried out in triplicate. All errors
shown are the mean±s.d. Student’s t-test was used to assess the
significance of the differences in cell proliferation in vitro. For
xenograft data, one-way analysis of variance followed by a
Bonferroni’s multiple comparison test was performed to determine
the statistical significance on most data sets. When only two
groups are compared, Student’s t-test was applied. All values are
represented as the mean±s.d. Data generated in these studies were
normally distributed as assessed by the method of Kolmogorov
and Smirnov. The type-1 error is 0.05. Statistics were calculated
using Prism 3 for Mac (GraphPad Software Inc., San Diego, CA,
USA).
RESULTS
In vitro angiogenesis
In this study, a coculture model was used, in which endothelial
cells are cocultured with fibroblasts in an optimised medium from
TCS Cellworks. The pro-angiogenic factor VEGF (2ngml
 1) was
used to further stimulate vessel formation in this assay, and the
capacity for STX243 to inhibit the VEGF-stimulated angiogenesis
was assessed. The representative high-resolution scans of the wells
clearly show that 100nM STX243-inhibited VEGF-stimulated vessel
formation (Figure 2A). Quantification of the scans, using an earlier
validated method (Newman et al, 2004), shows that STX243 at
100nM completely blocked all tubule formation (Figure 2B). At
50nM, STX243 still causes a significant inhibition of vessel
formation. However, at 25nM, the effects of STX243 are less
pronounced, resulting in only a small inhibition.
In vivo tumour efficacy
In the MDA-MB-231 study, significant tumour growth inhibition
was observed in the mice that were dosed daily with STX243
(40mgkg
 1, orally) and STX140 (20mgkg
 1, orally) (Figure 3A).
Compared with the vehicle-only animals, tumour growth inhibi-
tion of 72±13% (Po0.01) and 63±7% (Po0.05) was attained
with STX243 and STX140, respectively, after 21 days of drug
administration. No significant tumour inhibition was observed
with either dose of 2-MeOE2 (40 or 75mgkg
 1, orally daily) used
in this investigation.
MCF-7wt and paclitaxel-resistant (MCF-7dox40) xenograft
tumours were used in the in vivo resistance study. Both STX243
and paclitaxel significantly inhibited the growth of the MCF-7wt
tumours (Po0.01 and Po0.05, respectively; Figure 3B). Compared
with the vehicle-only animals, the percentage of tumour growth
inhibition for STX243 and paclitaxel was 87±5% and 87±6%,
respectively. In contrast, only STX243 was capable of significantly
inhibiting the growth of the MCF-7dox40 tumours (Po0.05;
Figure 3C). In comparison with the vehicle-only animals, growth
inhibition of 74±4% was observed with STX243 at the end of the
28-day dosing period.
In vivo angiogenesis assay
In vivo angiogenesis in Matrigel plugs without bFGF was not
observed (Figure 4A). The addition of bFGF to Matrigel stimulated
angiogenesis and caused a 410-fold increase in fluorescence of the
plugs (Figure 4B and E). This growth of new blood vessels was
significantly inhibited by administering either STX243 or STX140
to the animals (Po0.001 for all of the doses investigated) (Figure
4C, D and E). When compared with the animals that received
bFGF-only, the level of angiogenesis was reduced by 50±6% using
10mgkg
 1 of STX243 and 72±5% using 10mgkg
 1 of STX140.
When the dose of STX243 was increased, the level of fluorescence
associated with the Matrigel plugs decreased.
Pharmacokinetics of STX243
The pharmacokinetic parameters of STX243 were assessed in adult
female Wistar rats. Earlier we have shown the pharmacokinetics of
STX140 (Ireson et al, 2004). Figure 5 shows typical HPLC traces
that were obtained after the animals were dosed either intrave-
nously or orally with 40mgkg
 1 of STX243. Using the HPLC
method described earlier, STX243 was separated from the putative
metabolite STX1813 and the internal standard progesterone. The
retention times for the three compounds were 13.4, 16.2 and
25.8min for STX243, STX1813 (data not shown) and progesterone,
respectively.
STX243 was detected at all of the time points studied apart from
the initial 5-min time point after the animals were dosed orally
with 10mgkg
 1 of STX243 (Figure 6). The highest concentrations
STX243 VEGF
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Figure 2 Inhibition of angiogenesis by STX243 in vitro. STX243 disrupts
the ability of endothelial cells to form vessel-like structures. The non-
computer enhanced high-resolution scans of each well show the staining of
the CD31-positive endothelial cells, which form vessel-like structures (A).
A dose-dependent effect of STX243 on blood vessel formation is
observed. All columns represent cells grown in VEGF supplemented
media (B). Data represent mean±s.d.; n¼3; *Po0.05 and ***Po0.001
significance compared with the control group.
The in vivo properties of STX243
MFC Parsons et al
1436
British Journal of Cancer (2008) 99(9), 1433–1441 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sof STX243 were found in the plasma 4 and 8h after the animals had
been orally dosed with 10 or 40mgkg
 1 of STX243 respectively.
The bioavailability of STX243 increased from 18 to 31% when the
administered dose was lowered from 40 to 10mgkg
 1 (Table 1).
Similar distribution (t1/2a) and elimination (t1/2b) half-life values
were attained after intravenous administration regardless of the
dose of STX243 administered. The calculated elimination half-life
of STX243 was 1.88h after 40mgkg
 1 oral administration.
However, an increased elimination half-life of 11.40h was attained
when the mice were dosed orally with 10mgkg
 1. The increased
value was primarily because of the high concentration of STX243
detected in the plasma 24h after dosing. High clearance and
volume of distribution values were observed under all dosing
conditions. The values observed were particularly apparent when
STX243 was administered orally, with clearance values above
700mlkg
 1h
 1 and volumes of distribution above 12lkg
 1 for
both doses under investigation. No metabolism of STX243 to
STX1813 was detected in any of the plasma samples.
None of the animals lost a significant amount of weight in any of
the investigations conducted.
DISCUSSION
The steroidal-based entity STX243 has been developed as a
potentially active antiangiogenic and antitumour drug. The
objectives of this investigation were to assess the in vivo properties
of STX243 and compare the biological properties of this drug with
two structurally similar compounds STX140 and 2-MeOE2.
Tumour growth inhibition was examined in two breast cancer
models and the antiangiogenic potential of STX243 was evaluated
using a Matrigel plug-based assay. Preclinical studies have shown
that the addition of sulphamate groups to steroidal-based
compounds can increase their bioavailability, as showed by earlier
investigations that compared the pharmacokinetics of 2-MeOE2
with STX140 in female Wistar rats (Ireson et al, 2004). To compare
the biological properties of all three compounds, the same animal
model was used in this study to examine the pharmacokinetics of
STX243.
STX243 is a potent orally active compound, as highlighted by the
tumour growth inhibition studies. The results of the MDA-MB-231
xenograft study showed that there was no significant difference
between the level of tumour growth inhibition obtained with
40mgkg
 1 of STX243 and 20mgkg
 1 of STX140 (P40.05).
In contrast to the results with STX140 and STX243, 2-MeOE2 did
not inhibit the growth of the tumours at either dose used (40 or
75mgkg
 1) in this investigation. This finding is in agreement with
numerous in vitro and in vivo investigations. Earlier cell
proliferation studies have shown that STX243 and STX140 are
considerably more potent than 2-MeOE2, with some investigations
highlighting a 10-fold difference in activity (Day et al, 2003; Wood
et al, 2004; Leese et al, 2005). In vivo STX140 has showed the
capability to restrict tumour growth, whereas 2-MeOE2 has been
shown to be comparatively ineffective (Ryschich et al, 2003; Ireson
et al, 2004; Utsumi et al, 2005).
The growth of MCF-7 xenograft tumours was also inhibited by
STX243, thereby proving that the steroidal-based compound is
active against both ERþ and ER  tumours. In this study, both
STX243 and paclitaxel were capable of inhibiting the growth of the
MCF-7wt tumours. However, the growth of the MCF-7dox40
tumours was inhibited only by STX243. This finding indicates that
STX243 is not a substrate for the multidrug resistance protein,
P-glycoprotein, which is overexpressed in this cell line (Scheffer
et al, 2000). The results obtained here with paclitaxel are supported
by earlier in vivo investigations that have shown that the
taxane is ineffective at inhibiting the growth of breast carcinoma
tumours that overexpress P-glycoprotein (Newman et al, 2000;
Loganzo et al, 2003). Recent studies have shown that
STX140 is also capable of inhibiting the growth of MCF-7dox40
tumours (Newman et al, 2008).
The results of the Matrigel plug-based assay clearly show the
antiangiogenic potential of STX243. The steroidal-based
compound significantly inhibited the angiogenesis of the
bFGF-stimulated Matrigel plugs. Comparable levels of fluorescence
were found in the plugs from the animals treated with either
STX243 or STX140. However, in agreement with the tumour
growth inhibition studies, a higher dose of STX243 was required to
obtain the same antiangiogenic effect. Three doses of STX243 were
used in this study; as the dose increased there was a corresponding
decrease in the extent of angiogenesis. Earlier experiments in our
laboratory have shown that STX140 is more efficacious than
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Figure 3 Inhibition of tumour growth in MF-1 nude mice xenograft
models. In the MDA-MB-231 study (A) the animals were randomised into
five treatment groups when the tumours reached the required volume.
These groups were as follows: vehicle-only, STX140 (20mgkg
 1, orally),
STX243 (40mgkg
 1, orally) and 2-MeOE2 (40 and 75mgkg
 1, orally). All
of the compounds were administered on a daily basis. In the MCF-7wt (B)
and MCF-7dox40 (C) investigations, the mice were randomised to receive
vehicle-only (daily), STX243 (40mgkg
 1, orally daily) and paclitaxel
(15mgkg
 1, intravenous weekly). Data represent mean±s.d., n¼5 for
all groups, except for the vehicle only group for Figure 3A when n¼7. Each
drug treatment was compared with the control group for statistical
significance: *Po0.05 and **Po0.01.
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s2-MeOE2 in reducing the level of angiogenesis in Matrigel plugs.
Angiogenesis inhibition was only observed when the mice were
dosed orally with 50mgkg
 1 of 2-MeOE2, whereas no significant
inhibition was observed using a 10mgkg
 1 dose of the drug
(Chander et al, 2007). Judging from the in vitro angiogenesis kit
results, it is likely that STX243 disrupts new vessel formation in
vivo, and therefore results in a tumour growth reduction.
The pharmacokinetics of STX140 and 2-MeOE2 have been
analysed earlier using an identical model as described here. Both
drugs were administered to the animals orally and intravenously
using a dose of 10mgkg
 1. The maximum concentrations of
STX140 found in the plasma after oral and intravenous dosing
were 3.9 and 6.6mgml
 1, respectively, and an average oral
bioavailability of 85% was observed. In contrast, 2-MeOE2 was
rapidly cleared from the plasma. Using HPLC, no 2-MeOE2 was
detected in the plasma after oral administration and 1h after
intravenous dosing the concentration of 2-MeOE2 in the plasma
was below the LOD (Ireson et al, 2004).
The results obtained in this study with STX243 show that the
compound can be easily detected in plasma up to 24h after
intravenous or oral administration, using doses of 10 or
40mgkg
 1. This finding indicates that STX243 is considerably
more biologically available than 2-MeOE2. The bioavailability of
STX243 was 18% when the drug was administered at a dose of
40mgkg
 1 and increased to 31% when the dose was lowered to
10mgkg
 1. Therefore, in this pharmacokinetic model, STX243 is
less bioavailable than STX140. Despite the differences in oral
bioavailability, a similar plasma profile was observed for both
drugs. For example, the peak concentration of STX243 in plasma
was achieved 4h after oral administration, when a dose of
10mgkg
 1 was used. Similarly, the peak plasma concentration of
STX140 was obtained 3h after oral administration; the 4h time
point being omitted. For both drugs, a two-compartment model
was found to be the best approximation to the intravenous data
obtained. In addition, no significant metabolism of STX243 or
STX140 was observed after intravenous or oral administration in
either of the studies (Ireson et al, 2004).
The pharmacokinetics of STX243, STX140 and 2-MeOE2 may
provide a possible explanation for the angiogenesis and tumour
growth inhibition data attained. In the tumour growth inhibition
studies, 2-MeOE2 was ineffective at retarding tumour growth at
either dose used. This finding is not surprising, as 2-MeOE2
displays very limited oral bioavailability. Both STX243 and STX140
are capable of inhibiting tumour growth and restricting the level of
angiogenesis following oral administration. However, to achieve
the same therapeutic effect, a higher dose of STX243 than STX140
was required. This finding is supported by the pharmacokinetic
results, which shows that STX140 has higher bioavailability than
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Figure 4 The inhibition of angiogenesis in C57BL/6J mice Matrigel plug-based model. The Matrigel plugs were photographed to show the extent of
vascularisation after the mice had received the following treatments: control (A), bFGF-only (B), bFGF and STX140 (10mgkg
 1 orally) (C) and bFGF and
STX243 (10mgkg
 1 orally) (D). The plugs were subsequently dissolved with Dispase and the fluorescence of the FITC-dextran was used to quantify the
extent of angiogenesis (E). Data represent mean±s.d., n¼5. Each drug treatment was compared with the bFGF-only group for statistical significance:
***Po0.001.
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sSTX243 when both drugs are administered orally at the same dose.
In addition, these studies indicate that STX243 is removed
comparatively quickly from plasma, as shown by the higher half-
life times generally observed for STX140 and the high clearance
levels calculated for STX243 (Ireson et al, 2004).
The sole structural difference between STX140 and STX243 is
the replacement of the oxygen atom of the 2-methoxy group with a
methylene (CH2) group in STX243. Although this change is
minimal, it is clearly sufficient to impact significantly on both
in vitro antiproliferative activity and the observed, in vivo,
antitumour activity. Given that the 2-methoxy and 2-ethyl groups
of STX140 and STX243 are of near identical size, steric factors can
be reasonably discounted. The effects of the respective C-2
substituents on the electron density of the A-ring are also unlikely
to greatly influence the potential electrostatic p–p interactions
between the aromatic ring and proximal residues in the site of
action. It may be that the greater hydrophobic nature of the ethyl
group of STX243 (with respect to the methoxy group of STX140)
allows for enhanced interaction with the colchicine-binding site on
1
2 0.1 mAU
05 2 5 20 15 10 30
Time (min)
Figure 5 HPLC chromatograms from the STX243 pharmacokinetic
experiments. STX243 was administered either intravenously or orally at
two different doses (10 or 40mgkg
 1) to female Wistar rats. Control
animals received vehicle-only. STX243 was extracted from the plasma using
solid phase extraction and the extracts were analysed using HPLC.
The chromatograms shown are: control (A), STX243 (40mgkg
 1,
orally) (B) and STX243 (40mgkg
 1, intravenously) (C). In the
chromatograms shown, the rats were culled 3h after dosing with
STX243. Peaks 1 and 2 correspond respectively to STX243 and the
internal standard (progesterone).
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Figure 6 Concentration of STX243 in rat plasma after a single oral
administration (A) or a single intravenous injection of STX243 (B). Animals
were dosed with either 10 or 40mgkg
 1 STX243. Plasma samples were
evaluated according to the HPLC analysis procedure described in the
Materials and Methods section. Data represent mean±s.d., n¼3.
Table 1 Summary of the pharmacokinetic data obtained after the oral or intravenous administration of STX243 at two separate doses (10 and
40mgkg
 1)
PK parameter Intravenous (40mgkg
 1) Oral (40mgkg
 1) Intravenous (10mgkg
 1) Oral (10mgkg
 1)
Cmax (mgml
 1) 44.85 1.76 13.14 0.64
t1/2a (h) 0.16 — 0.38 —
t1/2b (h) 3.18 1.88 4.78 11.40
AUC (hmgml
 1) 126 23 42 13
AUMC (h
2mgml
 1) 558 157 267 219
MRT (h) 4.44 6.93 6.28 16.79
Cl (mlkg
 1h
 1) 318 1764 235 766
VD (lkg
 1) 1.41 12.23 1.48 12.86
Bioavailability (% F) — 18.0 — 30.7
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stubulin, with which STX243 is presumed to interact, and thus
delivers the observed increase in antiproliferative activity in vitro
(Leese et al, 2005).
A key advantage of the 2-ethyloestradiol-derived STX243 over
its 2-methoxy congener (STX140) is the facile and high yielding
manner, in which it is synthesised. The key synthetic intermediate,
2-ethyloestradiol, is generated from oestradiol in six steps and
greater than 50% overall yield with numerous crystallisable
intermediates (thus allowing for removal of any potential
oestrogenic impurity) and requiring only one chromatographic
purification (Bubert et al, 2007). The synthesis of STX243 is thus
highly efficient and well suited to the manufacture of
large quantities of material, a significant consideration for
candidate drugs.
In conclusion, the results presented here show the in vivo
efficacy of the steroidal-based compound STX243. This study
shows that STX243 has favourable pharmacokinetic properties and
is capable of impeding the growth of both ERþ and ER  breast
cancer tumours. The results of the Matrigel plug-based assay prove
that STX243 is a potent angiogenesis inhibitor. Importantly, these
studies have proved that the clinically relevant agent 2-MeOE2 is
comparatively inactive in vivo at the doses used in this
investigation. With proven preclinical efficacy, it is anticipated
that STX243 will have considerable clinical potential in treating
patients with various oncological conditions.
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